{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:08:32Z","timestamp":1781525312980,"version":"3.54.1"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"High-level Public Health Technical Talent Project of Beijing Municipal Health Commission","award":["No. Discipline Backbone -02-28"],"award-info":[{"award-number":["No. Discipline Backbone -02-28"]}]},{"name":"National Regional Medical Center Clinical Research","award":["No. KCZL202401"],"award-info":[{"award-number":["No. KCZL202401"]}]},{"name":"Scientific Research Innovation Project","award":["No. KCDL202402"],"award-info":[{"award-number":["No. KCDL202402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01928-0","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:18:08Z","timestamp":1761700688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Tianyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"5","key":"1928_CR1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2025","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: global burden of disease study. J Hepatol. 2025;82(5):851\u201360.","journal-title":"J Hepatol"},{"key":"1928_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030614","author":"J Zhang","year":"2023","unstructured":"Zhang J, Hu C, Xie X, Qi L, Li C, Li S. Immune checkpoint inhibitors in HBV-caused hepatocellular carcinoma therapy. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11030614.","journal-title":"Vaccines"},{"key":"1928_CR3","doi-asserted-by":"crossref","first-page":"1531249","DOI":"10.3389\/fimmu.2025.1531249","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Zeng Z, Chen S, Zhou D, Tong G, Du D. Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review. Front Immunol. 2025;16:1531249.","journal-title":"Front Immunol"},{"issue":"3","key":"1928_CR4","volume":"1880","author":"W Zhang","year":"2025","unstructured":"Zhang W, Hong X, Xiao Y, Wang H, Zeng X. Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2025;1880(3):189310.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1928_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061663","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061663.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"1928_CR6","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers16234059","volume":"16","author":"K Krupa","year":"2024","unstructured":"Krupa K, Fudalej M, Cencelewicz-Lesikow A, Badowska-Kozakiewicz A, Czerw A, Deptala A. Current treatment methods in hepatocellular carcinoma. Cancers (Basel). 2024;16(23):4059.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1928_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","volume":"30","author":"K Sankar","year":"2024","unstructured":"Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30(1):1\u201315.","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"1928_CR8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1928_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12985-019-1183-z","volume":"16","author":"F Kong","year":"2019","unstructured":"Kong F, You H, Kong D, Zheng K, Tang R. The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis. Virol J. 2019;16(1):73.","journal-title":"Virol J"},{"key":"1928_CR10","volume":"13","author":"H You","year":"2022","unstructured":"You H, Qin S, Zhang F, Hu W, Li X, Liu D, et al. Regulation of pattern-recognition receptor signaling by HBX during Hepatitis B virus infection. Front Immunol. 2022;13:829923.","journal-title":"Front Immunol"},{"issue":"1","key":"1928_CR11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12964-023-01091-7","volume":"21","author":"H You","year":"2023","unstructured":"You H, Wang X, Ma L, Zhang F, Zhang H, Wang Y, et al. Insights into the impact of hepatitis B virus on hepatic stellate cell activation. Cell Commun Signal. 2023;21(1):70.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"1928_CR12","doi-asserted-by":"crossref","first-page":"2421231","DOI":"10.1080\/21505594.2024.2421231","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Cao W, Wang S, Zhang L, Li X, Zhang Z, et al. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma. Virulence. 2024;15(1):2421231.","journal-title":"Virulence"},{"issue":"5","key":"1928_CR13","first-page":"e0680","volume":"9","author":"F Kong","year":"2025","unstructured":"Kong F, Bao E, Zhong Y, Wang Y, Liu R, Zhang H, et al. HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression. Hepatol Commun. 2025;9(5):e0680.","journal-title":"Hepatol Commun"},{"issue":"2","key":"1928_CR14","first-page":"639","volume":"47","author":"HJ You","year":"2024","unstructured":"You HJ, Ma LH, Wang X, Wang YX, Zhang HY, Bao ES, et al. Hepatitis B virus core protein stabilizes RANGAP1 to upregulate KDM2A and facilitate hepatocarcinogenesis. Cell Oncol (Dordr). 2024;47(2):639\u201355.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"1928_CR15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41416-022-02115-8","volume":"128","author":"H You","year":"2023","unstructured":"You H, Zhang N, Yu T, Ma L, Li Q, Wang X, et al. Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis. Br J Cancer. 2023;128(6):992\u20131004.","journal-title":"Br J Cancer"},{"key":"1928_CR16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijbiomac.2022.11.312","volume":"226","author":"H You","year":"2023","unstructured":"You H, Yuan D, Li Q, Zhang N, Kong D, Yu T, et al. Hepatitis B virus X protein increases LASP1 SUMOylation to stabilize HER2 and facilitate hepatocarcinogenesis. Int J Biol Macromol. 2023;226:996\u20131009.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"1928_CR17","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02731-21","volume":"10","author":"S Ahluwalia","year":"2022","unstructured":"Ahluwalia S, Ahmad B, Salim U, Ghosh D, Kamuju V, Ghosh A, et al. Hepatitis B virus-encoded HBsAg contributes to hepatocarcinogenesis by inducing the oncogenic long noncoding RNA LINC00665 through the NF-kappaB pathway. Microbiol Spectr. 2022;10(5):e0273121.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"1928_CR18","volume":"17","author":"S Naidu","year":"2025","unstructured":"Naidu S, Margeridon S. Chronic hepatitis B virus persistence: mechanisms and insights. Cureus. 2025;17(2):e78944.","journal-title":"Cureus"},{"issue":"8","key":"1928_CR19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","volume":"21","author":"JJ Feld","year":"2023","unstructured":"Feld JJ, Lok AS, Zoulim F. New perspectives on development of curative strategies for chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21(8):2040\u201350.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1928_CR20","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/jvi.64.7.3319-3330.1990","volume":"64","author":"F Birnbaum","year":"1990","unstructured":"Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol. 1990;64(7):3319\u201330.","journal-title":"J Virol"},{"issue":"2","key":"1928_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101938","volume":"30","author":"C Georgi","year":"2025","unstructured":"Georgi C, D\u2019Souza S, Osiowy C, Coffin CS, Cooper CL. Chronic hepatitis B virus persistence: mechanisms, consequences and implications for achieving cure. Ann Hepatol. 2025;30(2):101938.","journal-title":"Ann Hepatol"},{"issue":"2","key":"1928_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","volume":"71","author":"G Raimondo","year":"2019","unstructured":"Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397\u2013408.","journal-title":"J Hepatol"},{"issue":"3","key":"1928_CR23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","volume":"74","author":"ST Cheng","year":"2021","unstructured":"Cheng ST, Hu JL, Ren JH, Yu HB, Zhong S, Wai Wong VK, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol. 2021;74(3):522\u201334.","journal-title":"J Hepatol"},{"issue":"0","key":"1928_CR24","first-page":"0","volume":"0","author":"W Liu","year":"2025","unstructured":"Liu W, Zhang X, Deng Y, Wang D, Li H. Unfolding HBx for an epigenetic switch of HBV cccDNA minichromosome. Protein Cell. 2025;0(0):0.","journal-title":"Protein Cell"},{"issue":"3","key":"1928_CR25","volume":"6","author":"Y Xue","year":"2017","unstructured":"Xue Y, Wang MJ, Yang ZT, Yu DM, Han Y, Huang D, et al. Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant. Emerg Microbes Infect. 2017;6(3):e15.","journal-title":"Emerg Microbes Infect"},{"key":"1928_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virusres.2015.08.004","volume":"210","author":"S Li","year":"2015","unstructured":"Li S, Zhao K, Liu S, Wu C, Yao Y, Cao L, et al. HBsAg sT123N mutation induces stronger antibody responses to HBsAg and HBcAg and accelerates in vivo HBsAg clearance. Virus Res. 2015;210:119\u201325.","journal-title":"Virus Res"},{"issue":"10","key":"1928_CR27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3748\/wjg.v30.i10.1295","volume":"30","author":"H Ma","year":"2024","unstructured":"Ma H, Yan QZ, Ma JR, Li DF, Yang JL. Overview of the immunological mechanisms in hepatitis B virus reactivation: implications for disease progression and management strategies. World J Gastroenterol. 2024;30(10):1295\u2013312.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1928_CR28","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.3390\/cimb45100521","volume":"45","author":"C Medina","year":"2023","unstructured":"Medina C, Garc\u00eda AH, Crespo FI, Toro FI, Mayora SJ, De Sanctis JB. A synopsis of Hepatitis C virus treatments and future perspectives. Curr Issues Mol Biol. 2023;45(10):8255\u201376.","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"1928_CR29","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41423-021-00729-1","volume":"18","author":"L Wang","year":"2021","unstructured":"Wang L, Sun Y, Song X, Wang Z, Zhang Y, Zhao Y, et al. Hepatitis B virus evades immune recognition via RNA adenosine deaminase ADAR1-mediated viral RNA editing in hepatocytes. Cell Mol Immunol. 2021;18(8):1871\u201382.","journal-title":"Cell Mol Immunol"},{"key":"1928_CR30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","volume":"11","author":"P Fisicaro","year":"2020","unstructured":"Fisicaro P, Barili V, Rossi M, Montali I, Vecchi A, Acerbi G, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol. 2020;11:849.","journal-title":"Front Immunol"},{"issue":"2","key":"1928_CR31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.31725","volume":"74","author":"C De Pasquale","year":"2021","unstructured":"De Pasquale C, Campana S, Barberi C, Sidoti Migliore G, Oliveri D, Lanza M, et al. Human hepatitis B virus negatively impacts the protective immune crosstalk between natural killer and dendritic cells. Hepatology. 2021;74(2):550\u201365.","journal-title":"Hepatology"},{"key":"1928_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126649","author":"E Binatti","year":"2022","unstructured":"Binatti E, Gerussi A, Barisani D, Invernizzi P. The role of macrophages in liver fibrosis: new therapeutic opportunities. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126649.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1928_CR33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41423-020-00560-0","volume":"18","author":"K Liu","year":"2021","unstructured":"Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol. 2021;18(1):38\u201344.","journal-title":"Cell Mol Immunol"},{"key":"1928_CR34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60095","author":"M Marotel","year":"2021","unstructured":"Marotel M, Villard M, Drouillard A, Tout I, Besson L, Allatif O, et al. Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.60095.","journal-title":"Elife"},{"key":"1928_CR35","doi-asserted-by":"crossref","first-page":"1067362","DOI":"10.3389\/fimmu.2022.1067362","volume":"13","author":"W Cao","year":"2022","unstructured":"Cao W, Lu H, Zhang L, Wang S, Deng W, Jiang T, et al. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN \u03b1-2a therapy. Front Immunol. 2022;13:1067362.","journal-title":"Front Immunol"},{"key":"1928_CR36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1928_CR37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/21505594.2022.2028483","volume":"13","author":"YC Chuang","year":"2022","unstructured":"Chuang YC, Tsai KN, Ou JJ. Pathogenicity and virulence of hepatitis B virus. Virulence. 2022;13(1):258\u201396.","journal-title":"Virulence"},{"issue":"5","key":"1928_CR38","volume":"91","author":"Z Wan","year":"2020","unstructured":"Wan Z, Zhou Z, Liu Y, Lai Y, Luo Y, Peng X, et al. Regulatory t cells and T helper 17 cells in viral infection. Scand J Immunol. 2020;91(5):e12873.","journal-title":"Scand J Immunol"},{"issue":"7","key":"1928_CR39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1928_CR40","volume":"2018","author":"L Guo","year":"2018","unstructured":"Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, et al. Recent advances in HBV reactivation research. BioMed Res Int. 2018;2018:2931402.","journal-title":"BioMed Res Int"},{"issue":"2","key":"1928_CR41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0042-6822(88)90127-4","volume":"167","author":"R Tur-Kaspa","year":"1988","unstructured":"Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988;167(2):630\u20133.","journal-title":"Virology"},{"key":"1928_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/v9040075","author":"T Tu","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017. https:\/\/doi.org\/10.3390\/v9040075.","journal-title":"Viruses"},{"issue":"2","key":"1928_CR43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.virusres.2012.02.013","volume":"165","author":"N Luo","year":"2012","unstructured":"Luo N, Cai Y, Zhang J, Tang W, Slagle BL, Wu X, et al. The c-terminal region of the hepatitis B virus X protein is required for its stimulation of HBV replication in primary mouse hepatocytes. Virus Res. 2012;165(2):170\u20138.","journal-title":"Virus Res"},{"issue":"1\u20132","key":"1928_CR44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","volume":"134","author":"M Nassal","year":"2008","unstructured":"Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134(1\u20132):235\u201349.","journal-title":"Virus Res"},{"key":"1928_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241","author":"CI Wooddell","year":"2017","unstructured":"Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aan0241.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1928_CR46","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","volume":"61","author":"A Bertoletti","year":"2012","unstructured":"Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61(12):1754\u201364.","journal-title":"Gut"},{"issue":"24","key":"1928_CR47","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.3748\/wjg.v20.i24.7675","volume":"20","author":"JW Jang","year":"2014","unstructured":"Jang JW. Hepatitis b virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20(24):7675\u201385.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1928_CR48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis b reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297\u2013309.","journal-title":"Gastroenterology"},{"issue":"4","key":"1928_CR49","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","volume":"79","author":"AD Ladd","year":"2024","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2024;79(4):926\u201340.","journal-title":"Hepatology"},{"issue":"3","key":"1928_CR50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"Iwamoto H, Shimose S, Shirono T, Niizeki T, Kawaguchi T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin Mol Hepatol. 2023;29(3):593\u2013604.","journal-title":"Clin Mol Hepatol"},{"issue":"13","key":"1928_CR51","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.3748\/wjg.v21.i13.3843","volume":"21","author":"MJ Song","year":"2015","unstructured":"Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843\u20139.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1928_CR52","first-page":"480","volume":"11","author":"BY Zhong","year":"2023","unstructured":"Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2023;11(2):480\u20139.","journal-title":"J Clin Transl Hepatol"},{"key":"1928_CR53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1743-422X-10-168","volume":"10","author":"Y Liu","year":"2013","unstructured":"Liu Y, Lou G, Wu W, Shi Y, Zheng M, Chen Z. Interferon-alpha sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-kappaB activation. Virol J. 2013;10:168.","journal-title":"Virol J"},{"issue":"6","key":"1928_CR54","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/hep.21572","volume":"45","author":"W Yeo","year":"2007","unstructured":"Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology. 2007;45(6):1382\u20139.","journal-title":"Hepatology"},{"issue":"5","key":"1928_CR55","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","volume":"75","author":"M Papatheodoridi","year":"2022","unstructured":"Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: a systematic review. Hepatology. 2022;75(5):1257\u201374.","journal-title":"Hepatology"},{"issue":"1","key":"1928_CR56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis b virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164(1):30\u201340.","journal-title":"Ann Intern Med"},{"key":"1928_CR57","volume":"8","author":"Y Chang","year":"2021","unstructured":"Chang Y, Jeong SW, Jang JY. Hepatitis B virus reactivation associated with therapeutic interventions. Front Med (Lausanne). 2021;8:770124.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1928_CR58","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cam4.1468","volume":"7","author":"J Wang","year":"2018","unstructured":"Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, et al. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Med. 2018;7(5):2021\u201333.","journal-title":"Cancer Med"},{"key":"1928_CR59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.freeradbiomed.2024.01.011","volume":"213","author":"J Yang","year":"2024","unstructured":"Yang J, Zheng L, Yang Z, Wei Z, Shao J, Zhang Y, et al. 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction. Free Radic Biol Med. 2024;213:233\u201347.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1928_CR60","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12964-024-01952-9","volume":"22","author":"M Sanati","year":"2024","unstructured":"Sanati M, Ghafouri-Fard S. The role of circRNAs in resistance to doxorubicin. Cell Commun Signal. 2024;22(1):572.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"1928_CR61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.31557\/APJCP.2025.26.1.5","volume":"26","author":"SJ Sinha","year":"2025","unstructured":"Sinha SJ, Kumar B, Prasad CP, Chauhan SS, Kumar M. Emerging research and future directions on doxorubicin: a snapshot. Asian Pac J Cancer Prev. 2025;26(1):5\u201315.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"1928_CR62","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","volume":"15","author":"W Yeo","year":"2004","unstructured":"Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15(11):1661\u20136.","journal-title":"Ann Oncol"},{"key":"1928_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/v11110997","author":"A Kostyusheva","year":"2019","unstructured":"Kostyusheva A, Brezgin S, Bayurova E, Gordeychuk I, Isaguliants M, Goptar I, et al. ATM and ATR expression potentiates HBV replication and contributes to reactivation of HBV infection upon DNA damage. Viruses. 2019. https:\/\/doi.org\/10.3390\/v11110997.","journal-title":"Viruses"},{"issue":"10","key":"1928_CR64","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1541-7786.MCR-09-0112","volume":"7","author":"YL Chung","year":"2009","unstructured":"Chung YL, Tsai TY. Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy. Mol Cancer Res. 2009;7(10):1672\u201385.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"1928_CR65","volume":"10","author":"YF Chen","year":"2015","unstructured":"Chen YF, Chong CL, Wu YC, Wang YL, Tsai KN, Kuo TM, et al. Doxorubicin activates hepatitis B Virus replication by elevation of p21 (Waf1\/Cip1) and C\/EBPalpha expression. PLoS ONE. 2015;10(6):e0131743.","journal-title":"PLoS ONE"},{"issue":"2","key":"1928_CR66","volume":"29","author":"YR Lei","year":"2024","unstructured":"Lei YR, He XL, Li J, Mo CF. Drug resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Front Biosci (Landmark Ed). 2024;29(2):52.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"1928_CR67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbrc.2019.08.116","volume":"519","author":"R Li","year":"2019","unstructured":"Li R, Xu T, Wang H, Wu N, Liu F, Jia X, et al. Dysregulation of the miR-325-3p\/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun. 2019;519(2):358\u201365.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1928_CR68","volume":"19","author":"X Li","year":"2024","unstructured":"Li X, Kong D, Hu W, Zheng K, You H, Tang R, et al. Insight into the mechanisms regulating liver cancer stem cells by hepatitis B virus X protein. Infect Agent Cancer. 2024;19(1):56.","journal-title":"Infect Agent Cancer"},{"issue":"10","key":"1928_CR69","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/cas.13014","volume":"107","author":"Z Chen","year":"2016","unstructured":"Chen Z, Tang J, Cai X, Huang Y, Gao Q, Liang L, et al. HBx mutations promote hepatoma cell migration through the Wnt\/beta-catenin signaling pathway. Cancer Sci. 2016;107(10):1380\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"1928_CR70","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5483\/BMBRep.2019.52.5.312","volume":"52","author":"ME Jegal","year":"2019","unstructured":"Jegal ME, Jung SY, Han YS. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. BMB Rep. 2019;52(5):330\u20135 (Kim YJ).","journal-title":"BMB Rep"},{"issue":"5","key":"1928_CR71","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13402-024-00955-5","volume":"47","author":"P Zhou","year":"2024","unstructured":"Zhou P, Yao W, Liu L, Yan Q, Chen X, Wei X, et al. SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma. Cell Oncol (Dordr). 2024;47(5):1757\u201378.","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"1928_CR72","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1111\/j.1365-2893.2011.01463.x","volume":"18","author":"Y Liu","year":"2011","unstructured":"Liu Y, Lou G, Wu W, Zheng M, Shi Y, Zhao D, et al. Involvement of the NF-kappaB pathway in multidrug resistance induced by HBx in a hepatoma cell line. J Viral Hepat. 2011;18(10):e439\u201346.","journal-title":"J Viral Hepat"},{"issue":"48","key":"1928_CR73","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.3748\/wjg.v27.i48.8302","volume":"27","author":"XC Wei","year":"2021","unstructured":"Wei XC, Xia YR, Zhou P, Xue X, Ding S, Liu LJ, et al. Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J Gastroenterol. 2021;27(48):8302\u201322.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1928_CR74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12985-020-01339-5","volume":"17","author":"J Ruan","year":"2020","unstructured":"Ruan J, Sun S, Cheng X, Han P, Zhang Y, Sun D. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro. Virol J. 2020;17(1):89.","journal-title":"Virol J"},{"issue":"1","key":"1928_CR75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.virs.2024.01.001","volume":"39","author":"J Li","year":"2024","unstructured":"Li J, Lin Y, Wang X, Lu M. Interconnection of cellular autophagy and endosomal vesicle trafficking and its role in hepatitis B virus replication and release. Virol Sin. 2024;39(1):24\u201330.","journal-title":"Virol Sin"},{"key":"1928_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092101","author":"Y Lin","year":"2020","unstructured":"Lin Y, Zhao Z, Huang A, Lu M. Interplay between cellular autophagy and hepatitis B virus replication: a systematic review. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9092101.","journal-title":"Cells"},{"issue":"6","key":"1928_CR77","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07357907.2022.2055050","volume":"40","author":"F Danesh Pouya","year":"2022","unstructured":"Danesh Pouya F, Rasmi Y, Nemati M. Signaling pathways involved in 5-FU drug resistance in cancer. Cancer Invest. 2022;40(6):516\u201343.","journal-title":"Cancer Invest"},{"issue":"1","key":"1928_CR78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.18632\/aging.203793","volume":"14","author":"G Zhang","year":"2022","unstructured":"Zhang G, Luo X, Wang Z, Xu J, Zhang W, Chen E, et al. TIMP-2 regulates 5-Fu resistance via the ERK\/MAPK signaling pathway in colorectal cancer. Aging (Albany NY). 2022;14(1):297\u2013315.","journal-title":"Aging (Albany NY)"},{"key":"1928_CR79","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.2147\/OTT.S108929","volume":"9","author":"K Yang","year":"2016","unstructured":"Yang K, Gao K, Hu G, Wen Y, Lin C, Li X. CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK\/MEK\/ERK signal pathway in colorectal cancer. Onco Targets Ther. 2016;9:7285\u201395.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"1928_CR80","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1349-7006.2007.00591.x","volume":"98","author":"C Chung","year":"2007","unstructured":"Chung C, Park SG, Park YM, Joh JW, Jung G. Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation. Cancer Sci. 2007;98(11):1758\u201366.","journal-title":"Cancer Sci"},{"issue":"4","key":"1928_CR81","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s12032-009-9363-0","volume":"27","author":"Y He","year":"2010","unstructured":"He Y, Sun HQ, He XE, Wang WL, Lei JH. Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells. Med Oncol. 2010;27(4):1227\u201333.","journal-title":"Med Oncol"},{"key":"1928_CR82","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12935-015-0269-y","volume":"15","author":"G Yu","year":"2015","unstructured":"Yu G, Chen X, Chen S, Ye W, Hou K, Liang M. Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell Int. 2015;15:116.","journal-title":"Cancer Cell Int"},{"issue":"23","key":"1928_CR83","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.3748\/wjg.v10.i23.3522","volume":"10","author":"J Guan","year":"2004","unstructured":"Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L. Involvement of extracellular signal-regulated kinase\/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol. 2004;10(23):3522\u20137.","journal-title":"World J Gastroenterol"},{"key":"1928_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081065","author":"KJ Su","year":"2019","unstructured":"Su KJ, Yu YL. Downregulation of SHIP2 by hepatitis B virus X promotes the metastasis and chemoresistance of hepatocellular carcinoma through SKP2. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11081065.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1928_CR85","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7150\/ijbs.12310","volume":"12","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Ghosh S, Dasgupta D, Ghosh A, Datta S, Sikdar N, et al. Hepatitis B virus X protein upregulates hELG1\/ ATAD5 expression through E2F1 in hepatocellular carcinoma. Int J Biol Sci. 2016;12(1):30\u201341.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"1928_CR86","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/1389557523666230825144150","volume":"24","author":"F Sheikhnia","year":"2024","unstructured":"Sheikhnia F, Maghsoudi H, Majidinia M. The critical function of microRNAs in developing resistance against 5- fluorouracil in cancer cells. Mini Rev Med Chem. 2024;24(6):601\u201317.","journal-title":"Mini Rev Med Chem"},{"issue":"25","key":"1928_CR87","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.7150\/thno.37717","volume":"9","author":"X Lin","year":"2019","unstructured":"Lin X, Zuo S, Luo R, Li Y, Yu G, Zou Y, et al. HBX-induced miR-5188 impairs FOXO1 to stimulate beta-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. Theranostics. 2019;9(25):7583\u201398.","journal-title":"Theranostics"},{"issue":"17","key":"1928_CR88","doi-asserted-by":"crossref","first-page":"24005","DOI":"10.18632\/oncotarget.8209","volume":"7","author":"KY Ng","year":"2016","unstructured":"Ng KY, Chai S, Tong M, Guan XY, Lin CH, Ching YP, et al. C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget. 2016;7(17):24005\u201317.","journal-title":"Oncotarget"},{"issue":"1","key":"1928_CR89","first-page":"118","volume":"11","author":"YF Qin","year":"2023","unstructured":"Qin YF, Zhou ZY, Fu HW, Lin HM, Xu LB, Wu WR, et al. Hepatitis B virus surface antigen promotes stemness of hepatocellular carcinoma through regulating microRNA-203a. J Clin Transl Hepatol. 2023;11(1):118\u201329.","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"1928_CR90","volume":"6","author":"JH Hung","year":"2011","unstructured":"Hung JH, Teng YN, Wang LH, Su IJ, Wang CC, Huang W, et al. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS ONE. 2011;6(12):e28977.","journal-title":"PLoS ONE"},{"key":"1928_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310858","author":"S Hamaya","year":"2023","unstructured":"Hamaya S, Oura K, Morishita A, Masaki T. Cisplatin in liver cancer therapy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241310858.","journal-title":"Int J Mol Sci"},{"key":"1928_CR92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cbi.2016.05.030","volume":"254","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang R, Yang H, Xiang Q, Jiang Q, He Q, et al. Hepatitis B virus enhances cisplatin-induced hepatotoxicity via a mechanism involving suppression of glucose-regulated protein of 78 Kda. Chem Biol Interact. 2016;254:45\u201353.","journal-title":"Chem Biol Interact"},{"issue":"7","key":"1928_CR93","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1128\/JVI.01841-10","volume":"85","author":"L Hu","year":"2011","unstructured":"Hu L, Chen L, Li L, Sun H, Yang G, Chang Y, et al. Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1. J Virol. 2011;85(7):3214\u201328.","journal-title":"J Virol"},{"issue":"1","key":"1928_CR94","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/s41598-018-21847-3","volume":"8","author":"X Li","year":"2018","unstructured":"Li X, Pan E, Zhu J, Xu L, Chen X, Li J, et al. Cisplatin enhances hepatitis B virus replication and PGC-1alpha expression through endoplasmic reticulum stress. Sci Rep. 2018;8(1):3496.","journal-title":"Sci Rep"},{"key":"1928_CR95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.freeradbiomed.2018.12.008","volume":"131","author":"X Chen","year":"2019","unstructured":"Chen X, Hu Y, Zhang W, Chen K, Hu J, Li X, et al. Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS\/JNK and inhibition of the Akt\/mTOR pathway. Free Radic Biol Med. 2019;131:225\u201336.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1928_CR96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2007.01.004","volume":"253","author":"AS Cheng","year":"2007","unstructured":"Cheng AS, Wong N, Tse AM, Chan KY, Chan KK, Sung JJ, et al. RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer Lett. 2007;253(1):43\u201352.","journal-title":"Cancer Lett"},{"issue":"7","key":"1928_CR97","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bcp.2010.06.003","volume":"80","author":"TC Kuo","year":"2010","unstructured":"Kuo TC, Chao CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem Pharmacol. 2010;80(7):1093\u2013102.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"1928_CR98","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1440-1746.2010.06243.x","volume":"25","author":"JS Lubel","year":"2010","unstructured":"Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25(5):864\u201371.","journal-title":"J Gastroenterol Hepatol"},{"key":"1928_CR99","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114489","volume":"153","author":"B Tang","year":"2025","unstructured":"Tang B, Ouyang H, Zheng S, Yu L, Xiao R, Wu L, et al. Doxorubicin promotes NK cell dysfunction and induces acute liver injury through kynurenine-AhR axis. Int Immunopharmacol. 2025;153:114489.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1928_CR100","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","volume":"59","author":"C Hsu","year":"2014","unstructured":"Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092\u2013100.","journal-title":"Hepatology"},{"issue":"2","key":"1928_CR101","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","volume":"33","author":"D Shouval","year":"2013","unstructured":"Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33(2):167\u201377.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1928_CR102","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1928_CR103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1358\/dot.2023.59.2.3507751","volume":"59","author":"R Chen","year":"2023","unstructured":"Chen R, Ielasi L, di Carlo A, Tovoli F. Donafenib in hepatocellular carcinoma. Drugs Today. 2023;59(2):83\u201390.","journal-title":"Drugs Today"},{"issue":"17","key":"1928_CR104","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.21037\/atm-20-2990","volume":"8","author":"Z Hou","year":"2020","unstructured":"Hou Z, Zhu K, Yang X, Chen P, Zhang W, Cui Y, et al. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. Ann Transl Med. 2020;8(17):1047.","journal-title":"Ann Transl Med"},{"issue":"27","key":"1928_CR105","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol. 2021;39(27):3002\u201311.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1928_CR106","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","volume":"10","author":"W Fan","year":"2024","unstructured":"Fan W, Zhu B, Chen S, Wu Y, Zhao X, Qiao L, et al. Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE versus TACE alone randomized clinical trial. JAMA Oncol. 2024;10(8):1047\u201354.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1928_CR107","volume":"5","author":"CAM Fulgenzi","year":"2023","unstructured":"Fulgenzi CAM, Scheiner B, Korolewicz J, Stikas CV, Gennari A, Vincenzi B, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials. JHEP Rep. 2023;5(5):100702.","journal-title":"JHEP Rep"},{"issue":"2","key":"1928_CR108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12072-022-10450-4","volume":"17","author":"J Lei","year":"2023","unstructured":"Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, et al. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatol Int. 2023;17(2):281\u201390.","journal-title":"Hepatol Int"},{"key":"1928_CR109","volume":"13","author":"J Shen","year":"2023","unstructured":"Shen J, Wang X, Wang N, Wen S, Yang G, Li L, et al. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. Front Cell Infect Microbiol. 2023;13:1179689.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1928_CR110","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.","journal-title":"Signal Transduct Target Ther"},{"key":"1928_CR111","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","DOI":"10.1056\/NEJMoa0708857"},{"issue":"6","key":"1928_CR112","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2016.69.5197","volume":"35","author":"R Jackson","year":"2017","unstructured":"Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of viral status on survival in patients receiving Sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol. 2017;35(6):622\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1928_CR113","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jgh.12898","volume":"30","author":"S Lim","year":"2015","unstructured":"Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol. 2015;30(6):1024\u201331.","journal-title":"J Gastroenterol Hepatol"},{"key":"1928_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/v14112355","author":"IC Lee","year":"2022","unstructured":"Lee IC, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, et al. Application and impact of antiviral therapy for patients with HBV-related hepatocellular carcinoma receiving sorafenib and lenvatinib treatment. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14112355.","journal-title":"Viruses"},{"issue":"6","key":"1928_CR115","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jgh.12910","volume":"30","author":"L Xu","year":"2015","unstructured":"Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015;30(6):1032\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"1928_CR116","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/liv.12805","volume":"35","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int. 2015;35(9):2147\u201354.","journal-title":"Liver Int"},{"key":"1928_CR117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2394-5079.158391","volume":"1","author":"HK Cho","year":"2015","unstructured":"Cho HK, Kim JR, Kim SY, Kyaw YY, Win AA, Cheong JH. Sorafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway. Hepatoma Res. 2015;1:97\u2013103.","journal-title":"Hepatoma Res"},{"issue":"1","key":"1928_CR118","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2014.09.015","volume":"355","author":"HY Kim","year":"2014","unstructured":"Kim HY, Jung HU, Yoo SH, Yoo KS, Cheong J, Park BS, et al. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression. Cancer Lett. 2014;355(1):61\u20139.","journal-title":"Cancer Lett"},{"key":"1928_CR119","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv190","author":"SH Wang","year":"2015","unstructured":"Wang SH, Yeh SH, Shiau CW, Chen KF, Lin WH, Tsai TF, et al. Sorafenib action in hepatitis B virus X-activated oncogenic androgen pathway in liver through SHP-1. J Natl Cancer Inst. 2015. https:\/\/doi.org\/10.1093\/jnci\/djv190.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1928_CR120","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"AL Cheng","year":"2012","unstructured":"Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452\u201365.","journal-title":"Eur J Cancer"},{"key":"1928_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223763","author":"N Esmael","year":"2024","unstructured":"Esmael N, Lubin I, Tur-Kaspa R, Zemel R. Hepatitis B virus-induced resistance to sorafenib and lenvatinib in hepatocellular carcinoma cells: implications for cell viability and signaling pathways. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16223763.","journal-title":"Cancers (Basel)"},{"key":"1928_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043263","author":"L Liu","year":"2023","unstructured":"Liu L, Lv Z, Wang M, Zhang D, Liu D, Zhu F. HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043263.","journal-title":"Int J Mol Sci"},{"key":"1928_CR123","volume":"157","author":"Y Gao","year":"2020","unstructured":"Gao Y, Fan X, Li N, Du C, Yang B, Qin W, et al. CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. Pharmacol Res. 2020;157:104800.","journal-title":"Pharmacol Res"},{"issue":"14","key":"1928_CR124","volume":"28","author":"J Lee","year":"2024","unstructured":"Lee J, Kim J, Lee R, Lee E, An HI, Kwon YJ, et al. SOD1 inhibition enhances sorafenib efficacy in HBV-related hepatocellular carcinoma by modulating PI3K\/Akt\/mTOR pathway and ROS-mediated cell death. J Cell Mol Med. 2024;28(14):e18533.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"1928_CR125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2014.07.004","volume":"352","author":"K Mao","year":"2014","unstructured":"Mao K, Zhang J, He C, Xu K, Liu J, Sun J, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014;352(2):245\u201352.","journal-title":"Cancer Lett"},{"issue":"1","key":"1928_CR126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13027-021-00359-2","volume":"16","author":"S Zhang","year":"2021","unstructured":"Zhang S, Li N, Sheng Y, Chen W, Ma Q, Yu X, et al. Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. Infect Agent Cancer. 2021;16(1):20.","journal-title":"Infect Agent Cancer"},{"issue":"179","key":"1928_CR127","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.24976\/Discov.Med.202335179.99","volume":"35","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu X, Luo M, Li Y, Li H. HBx modulates drug resistance of Sorafenib-resistant hepatocellular carcinoma cells. Discov Med. 2023;35(179):1035\u201342.","journal-title":"Discov Med"},{"issue":"5","key":"1928_CR128","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s13577-023-00945-z","volume":"36","author":"H He","year":"2023","unstructured":"He H, Zhou J, Cheng F, Li H, Quan Y. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination. Hum Cell. 2023;36(5):1773\u201389.","journal-title":"Hum Cell"},{"issue":"1","key":"1928_CR129","first-page":"15","volume":"13","author":"X Jin","year":"2025","unstructured":"Jin X, Dong H, Wang J, Ou G, Lai X, Tian X, et al. HBx facilitates drug resistance in hepatocellular carcinoma via CD133-regulated Self-renewal of liver cancer stem cells. J Clin Transl Hepatol. 2025;13(1):15\u201324.","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"1928_CR130","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1016\/j.ymthe.2021.04.011","volume":"29","author":"W Song","year":"2021","unstructured":"Song W, Zheng C, Liu M, Xu Y, Qian Y, Zhang Z, et al. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Mol Ther. 2021;29(8):2601\u201316.","journal-title":"Mol Ther"},{"issue":"1","key":"1928_CR131","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-020-0111-4","volume":"5","author":"X Lin","year":"2020","unstructured":"Lin X, Li AM, Li YH, Luo RC, Zou YJ, Liu YY, et al. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):13.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1928_CR132","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tranon.2018.02.015","volume":"11","author":"D Witt-Kehati","year":"2018","unstructured":"Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma cells with hepatitis B virus. Transl Oncol. 2018;11(2):511\u20137.","journal-title":"Transl Oncol"},{"issue":"14","key":"1928_CR133","doi-asserted-by":"crossref","first-page":"23507","DOI":"10.18632\/oncotarget.15183","volume":"8","author":"RHH Ching","year":"2017","unstructured":"Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee JMF, Ng IOL, et al. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3\/Nanog signaling pathway. Oncotarget. 2017;8(14):23507\u201316.","journal-title":"Oncotarget"},{"key":"1928_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235781","author":"LJ Liu","year":"2022","unstructured":"Liu LJ, Lv Z, Xue X, Xing ZY, Zhu F. Canonical WNT signaling activated by WNT7B contributes to L-HBs-mediated sorafenib resistance in hepatocellular carcinoma by inhibiting mitophagy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14235781.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1928_CR135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12876-022-02210-3","volume":"22","author":"NR Choi","year":"2022","unstructured":"Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, et al. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol. 2022;22(1):135.","journal-title":"BMC Gastroenterol"},{"key":"1928_CR136","doi-asserted-by":"crossref","first-page":"1032881","DOI":"10.3389\/fphar.2022.1032881","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Wang J, Ding X, Xu Y, Yu M, Wu H, et al. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy. Front Pharmacol. 2022;13:1032881.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1928_CR137","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11523-019-00651-7","volume":"14","author":"J Park","year":"2019","unstructured":"Park J, Cho J, Lim JH, Lee MH, Kim J. Relative efficacy of systemic treatments for patients with advanced hepatocellular carcinoma according to viral status: a systematic review and network meta-analysis. Target Oncol. 2019;14(4):395\u2013403.","journal-title":"Target Oncol"},{"key":"1928_CR138","volume":"12","author":"B Liu","year":"2022","unstructured":"Liu B, Shang X, Shi JY, Cui GZ, Li X, Wang NY. Early alpha-fetoprotein response is associated with survival in patients with HBV-related hepatocellular carcinoma receiving lenvatinib. Front Oncol. 2022;12:807189.","journal-title":"Front Oncol"},{"issue":"3","key":"1928_CR139","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s12094-024-03596-0","volume":"27","author":"Y Yao","year":"2025","unstructured":"Yao Y, Zhang M, Liu D, Liu X, Li Q, Wang X. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors. Clin Transl Oncol. 2025;27(3):1155\u201365.","journal-title":"Clin Transl Oncol"},{"key":"1928_CR140","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241309046","volume":"32","author":"B Sheng","year":"2025","unstructured":"Sheng B, Wang D, Wang J. Hepatitis B virus reactivation in patients with HBV-related advanced hepatocellular carcinoma undergoing lenvatinib and camrelizumab treatment. Cancer Control. 2025;32:10732748241309046.","journal-title":"Cancer Control"},{"key":"1928_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009165","author":"C Lu","year":"2024","unstructured":"Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009165.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1928_CR142","doi-asserted-by":"crossref","first-page":"107327481987221","DOI":"10.1177\/1073274819872216","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Fan W, Wang Y, Huang G, Li J. Apatinib for patients with sorafenib-refractory advanced hepatitis B virus related hepatocellular carcinoma: results of a pilot study. Cancer Control. 2019;26(1):1073274819872216.","journal-title":"Cancer Control"},{"key":"1928_CR143","first-page":"175883592093742","volume":"12","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Huang G, Miao H, Song Z, Zhang X, Fan W, et al. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920937422.","journal-title":"Ther Adv Med Oncol"},{"key":"1928_CR144","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.2147\/OTT.S286169","volume":"13","author":"G Yuan","year":"2020","unstructured":"Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study. Onco Targets Ther. 2020;13:12683\u201393.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"1928_CR145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12885-025-13605-2","volume":"25","author":"X Hong","year":"2025","unstructured":"Hong X, Guo Y, Shi W, Zhu K, Liang L, Lin L, et al. Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial. BMC Cancer. 2025;25(1):205.","journal-title":"BMC Cancer"},{"issue":"10064","key":"1928_CR146","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet"},{"issue":"9","key":"1928_CR147","volume":"96","author":"Z Lv","year":"2024","unstructured":"Lv Z, Liu L, You J, Zhou P, Su Y, Zhao K, et al. Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9. J Med Virol. 2024;96(9):e29894.","journal-title":"J Med Virol"},{"issue":"11","key":"1928_CR148","doi-asserted-by":"crossref","first-page":"e0313","DOI":"10.1097\/HC9.0000000000000313","volume":"7","author":"K Funato","year":"2023","unstructured":"Funato K, Miyake N, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, et al. Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA. Hepatol Commun. 2023;7(11):e0313.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1928_CR149","volume":"9","author":"D Ball","year":"2025","unstructured":"Ball D, Nault JC, Vithayathil M, Allaire M, Ganne-Carrie N, Campani C, et al. Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma. NPJ Precis Oncol. 2025;9(1):129.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1928_CR150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000525499","volume":"12","author":"C Hsu","year":"2023","unstructured":"Hsu C, Ducreux M, Zhu AX, Qin S, Ikeda M, Kim TY, et al. Hepatic events and viral kinetics in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab. Liver Cancer. 2023;12(1):44\u201356.","journal-title":"Liver Cancer"},{"issue":"3","key":"1928_CR151","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00432-024-05677-7","volume":"150","author":"R Wang","year":"2024","unstructured":"Wang R, Tan G, Lei D, Li Y, Gong J, Tang Y, et al. Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era. J Cancer Res Clin Oncol. 2024;150(3):158.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"1928_CR152","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1111\/liv.14994","volume":"41","author":"PR Galle","year":"2021","unstructured":"Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, et al. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: impact of liver disease aetiology. Liver Int. 2021;41(11):2759\u201367.","journal-title":"Liver Int"},{"issue":"4","key":"1928_CR153","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43(4):641\u201364.","journal-title":"Cancer Cell"},{"issue":"18","key":"1928_CR154","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.21037\/atm-20-6063","volume":"8","author":"J Chen","year":"2020","unstructured":"Chen J, Hu X, Li Q, Dai W, Cheng X, Huang W, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med. 2020;8(18):1187.","journal-title":"Ann Transl Med"},{"issue":"10","key":"1928_CR155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11864-024-01246-9","volume":"25","author":"H Dong","year":"2024","unstructured":"Dong H, Zhang Z, Ni M, Xu X, Luo Y, Wang Y, et al. The trend of the treatment of advanced hepatocellular carcinoma: combination of immunotherapy and targeted therapy. Curr Treat Options Oncol. 2024;25(10):1239\u201356.","journal-title":"Curr Treat Options Oncol"},{"issue":"Pt 3","key":"1928_CR156","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.semcancer.2022.01.005","volume":"86","author":"U Harkus","year":"2022","unstructured":"Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin Cancer Biol. 2022;86(Pt 3):799\u2013815.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1928_CR157","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00636-5","volume":"14","author":"J Tong","year":"2025","unstructured":"Tong J, Tan Y, Ouyang W, Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential. Exp Hematol Oncol. 2025;14(1):65.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1928_CR158","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):35.","journal-title":"Signal Transduct Target Ther"},{"key":"1928_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.033","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033.","journal-title":"J Hepatol"},{"issue":"4","key":"1928_CR160","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"10408","key":"1928_CR161","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"7","key":"1928_CR162","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1928_CR163","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682\u201393.","journal-title":"Gastroenterology"},{"issue":"1","key":"1928_CR164","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","volume":"60","author":"J Chen","year":"2011","unstructured":"Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res. 2011;60(1):47\u201353.","journal-title":"Inflamm Res"},{"issue":"5","key":"1928_CR165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"1928_CR166","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","volume":"143","author":"P Fisicaro","year":"2012","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Ravanetti L, Urbani S, et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology. 2012;143(6):1576\u201385.","journal-title":"Gastroenterology"},{"issue":"10","key":"1928_CR167","volume":"6","author":"E Zhang","year":"2011","unstructured":"Zhang E, Zhang X, Liu J, Wang B, Tian Y, Kosinska AD, et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS ONE. 2011;6(10):e26196.","journal-title":"PLoS ONE"},{"key":"1928_CR168","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","volume":"11","author":"B Li","year":"2020","unstructured":"Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, et al. Anti-PD-1\/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review. Front Immunol. 2020;11:1037.","journal-title":"Front Immunol"},{"issue":"1","key":"1928_CR169","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-023-10960-w","volume":"23","author":"D Huang","year":"2023","unstructured":"Huang D, Ke L, Cui H, Li S. Efficacy and safety of PD-1\/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2023;23(1):474.","journal-title":"BMC Cancer"},{"issue":"1","key":"1928_CR170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","volume":"12","author":"Z Xia","year":"2023","unstructured":"Xia Z, Zhang J, Chen W, Zhou H, Du D, Zhu K, et al. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):87.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"1928_CR171","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019;7(1):322.","journal-title":"J Immunother Cancer"},{"key":"1928_CR172","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072","author":"PC Lee","year":"2020","unstructured":"Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001072.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1928_CR173","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12879-022-07602-0","volume":"22","author":"X Hu","year":"2022","unstructured":"Hu X, Li R, Li Q, Zang M, Yuan G, Chen J. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infect Dis. 2022;22(1):614.","journal-title":"BMC Infect Dis"},{"key":"1928_CR174","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/JHC.S278527","volume":"7","author":"X Sun","year":"2020","unstructured":"Sun X, Hu D, Yang Z, Liu Z, Wang J, Chen J, et al. Baseline HBV loads do not affect the prognosis of patients with hepatocellular carcinoma receiving anti-programmed cell death-1 immunotherapy. J Hepatocell Carcinoma. 2020;7:337\u201345.","journal-title":"J Hepatocell Carcinoma"},{"key":"1928_CR175","volume":"13","author":"S Pan","year":"2022","unstructured":"Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, et al. Correlation of HBV DNA and hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with HBV infection undergoing PD-1 inhibition combinational therapy. Front Immunol. 2022;13:892618.","journal-title":"Front Immunol"},{"key":"1928_CR176","volume":"15","author":"Z Ji","year":"2024","unstructured":"Ji Z, Li J, Zhang S, Jia Y, Zhang J, Guo Z. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients. Front Immunol. 2024;15:1480520.","journal-title":"Front Immunol"},{"issue":"4","key":"1928_CR177","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","volume":"20","author":"S Yoo","year":"2022","unstructured":"Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment. Clin Gastroenterol Hepatol. 2022;20(4):898\u2013907.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1928_CR178","volume":"599","author":"A Kar","year":"2024","unstructured":"Kar A, Mukherjee S, Mukherjee S, Biswas A. Ubiquitin: a double-edged sword in hepatitis B virus-induced hepatocellular carcinoma. Virology. 2024;599:110199.","journal-title":"Virology"},{"issue":"2","key":"1928_CR179","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/AAC.01101-09","volume":"54","author":"P Bandi","year":"2010","unstructured":"Bandi P, Garcia ML, Booth CJ, Chisari FV, Robek MD. Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother. 2010;54(2):749\u201356.","journal-title":"Antimicrob Agents Chemother"},{"key":"1928_CR180","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/964082","volume":"2014","author":"S Hussain","year":"2014","unstructured":"Hussain S, Jhaj R, Ahsan S, Ahsan M, Bloom RE, Jafri SM. Bortezomib induced hepatitis B reactivation. Case Rep Med. 2014;2014:964082.","journal-title":"Case Rep Med"},{"issue":"6","key":"1928_CR181","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","volume":"56","author":"J Li","year":"2015","unstructured":"Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56(6):1710\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1928_CR182","volume":"178","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, et al. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacol Res. 2022;178:106181.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1928_CR183","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3.","journal-title":"Gastroenterology"},{"issue":"1","key":"1928_CR184","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.25602","volume":"56","author":"K Hoppe-Seyler","year":"2012","unstructured":"Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F. The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology. 2012;56(1):9\u201316.","journal-title":"Hepatology"},{"issue":"1","key":"1928_CR185","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Wang B, Huang S, Song Z, Wu J, Zhang E, et al. Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model. PLoS ONE. 2014;9(1):e85832.","journal-title":"PLoS ONE"},{"issue":"1","key":"1928_CR186","first-page":"18","volume":"4","author":"WL Xia","year":"2005","unstructured":"Xia WL, Shen Y, Zheng SS. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat Dis Int. 2005;4(1):18\u201322.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"1928_CR187","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3904\/kjim.2004.19.3.196","volume":"19","author":"SM Bang","year":"2004","unstructured":"Bang SM, Kim SS, Park SH, Ahn JY, Cho EK, Shin DB, et al. Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report. Korean J Intern Med. 2004;19(3):196\u20138.","journal-title":"Korean J Intern Med"},{"issue":"5","key":"1928_CR188","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4065\/82.5.638","volume":"82","author":"M Hamadani","year":"2007","unstructured":"Hamadani M, Benson DM Jr, Copelan EA. Thalidomide-induced fulminant hepatic failure. Mayo Clin Proc. 2007;82(5):638.","journal-title":"Mayo Clin Proc"},{"issue":"6176","key":"1928_CR189","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343(6176):1221\u20138.","journal-title":"Science"},{"issue":"3","key":"1928_CR190","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","volume":"12","author":"X Xu","year":"2015","unstructured":"Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol. 2015;12(3):309\u201316.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1928_CR191","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s44178-024-00082-z","volume":"3","author":"H Lin","year":"2024","unstructured":"Lin H, Dai Z, Huang L, Zhou X. Hepatitis b virus reactivation associated with CAR t-cell therapy. Holist Integr Oncol. 2024;3(1):16.","journal-title":"Holist Integr Oncol"},{"issue":"10","key":"1928_CR192","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","volume":"34","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu Y, Tan X, Pan B, Ge J, Qi K, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020;34(10):2704\u20137.","journal-title":"Leukemia"},{"issue":"6","key":"1928_CR193","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41409-023-01960-2","volume":"58","author":"S Fu","year":"2023","unstructured":"Fu S, Zhang Q, Jing R, Zu C, Ni F, Lv Y, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transplant. 2023;58(6):701\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1928_CR194","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2020004907","volume":"136","author":"W Cao","year":"2020","unstructured":"Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood. 2020;136(4):516\u20139.","journal-title":"Blood"},{"issue":"11","key":"1928_CR195","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/s41375-020-0913-y","volume":"34","author":"C Yang","year":"2020","unstructured":"Yang C, Xie M, Zhang K, Liu H, Liang A, Young KH, et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia. 2020;34(11):3055\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1928_CR196","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2807","volume":"39","author":"R Cui","year":"2021","unstructured":"Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, et al. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol Oncol. 2021;39(1):75\u201386.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1928_CR197","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/omi.2021.0052","volume":"25","author":"K Dzobo","year":"2021","unstructured":"Dzobo K. The role of viruses in carcinogenesis and molecular targeting: from infection to being a component of the tumor microenvironment. OMICS. 2021;25(6):358\u201371.","journal-title":"OMICS"},{"issue":"1","key":"1928_CR198","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12575-025-00281-6","volume":"27","author":"Y Zou","year":"2025","unstructured":"Zou Y, Wan X, Zhou Q, Zhu G, Lin S, Tang Q, et al. Mechanisms of drug resistance in hepatocellular carcinoma. Biol Proced Online. 2025;27(1):19.","journal-title":"Biol Proced Online"},{"issue":"3","key":"1928_CR199","volume":"1880","author":"F Sun","year":"2025","unstructured":"Sun F, Gao X, Li T, Zhao X, Zhu Y. Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: update and new challenges. Biochimica et Biophysica Acta (BBA). 2025;1880(3):189350.","journal-title":"Biochimica et Biophysica Acta (BBA)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01928-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:05Z","timestamp":1764917405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01928-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01928-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"334"}}